



**PRACTICAL MANAGEMENT OF TYPE 2 DIABETES
IN PATIENTS WITH CARDIOVASCULAR DISEASE**

Panelists	Has an affiliation with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this manuscript	Consulting fees / Honoraria	Officer, director, or in any other fiduciary role	Clinical Trials	Ownership / Partnership / Principal	Intellectual property rights	Other financial benefit
Dr. Mary Catherine MacSween	Yes	AstraZeneca, Merck, Sanofi Aventis	None	None	None	None	None
Dr. Nicholas Giacomantonio	Yes	Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Merck, Novartis, Pfizer, Sanofi Aventis, Servier	None	None	None	None	None
Dr. Lenley Adams	Yes	AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Sanofi Aventis, Novo Nordisk	None	None	None	None	None
Dr. Iqbal Bata	No		None	None	None	None	None
Michael Callaghan	No		None	None	None	None	None
Trish Colins	Yes	AstraZeneca, Eli Lilly, Johnson & Johnson, Novartis, Sanofi Aventis	None	None	None	None	None
Dr. Michel D'Astous	Yes	AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Pfizer, Sanofi Aventis, Servier	None	Novartis	None	None	None
Dr. Daniel Landry	No		None	None	None	None	None
Dr. Angela McGibbon	Yes	AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Novartis, Sanofi Aventis	None	None	None	None	Yes (Educational Grants)
Dr. Penelope Poyah	Yes	Pfizer, Alexion Pharma	Yes	None	None	None	None
Dr. Thomas Ransom	Yes	Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Lexicon, Intarcia, Sanofi Aventis, Servier, Novo Nordisk	None	None	None	None	None
Dr. J.E. van Wijk	No		None	None	None	None	None
Dr. Catherine Yu	No		None	None	None	None	None